Neogene Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Neogene Therapeutics's estimated annual revenue is currently $37.4M per year.
- Neogene Therapeutics's estimated revenue per employee is $193,750
- Neogene Therapeutics's total funding is $125M.
Employee Data
- Neogene Therapeutics has 193 Employees.
- Neogene Therapeutics grew their employee count by 21% last year.
Neogene Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP and Head Information Technology | Reveal Email/Phone |
3 | Head Human Resources | Reveal Email/Phone |
4 | VP, Head Business Development | Reveal Email/Phone |
5 | SVP, Technical Operations | Reveal Email/Phone |
6 | VP - Translational Sciences | Reveal Email/Phone |
7 | VP, Intellectual Property | Reveal Email/Phone |
8 | VP Corporate Strategy and Head EU Operations | Reveal Email/Phone |
9 | VP, Head Manufacturing and Facilities | Reveal Email/Phone |
10 | Head Quality Assurance | Reveal Email/Phone |
Neogene Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Neogene Therapeutics?
Neogene Therapeutics is a pre-clinical stage biotechnology company aiming to change the paradigm of treatment for solid cancers. Our mission is to provide cancer patients with T cell therapies targeting mutated proteins called neo-antigens, which are present on cancer cells as a consequence of DNA mutations. Neogene is developing novel technologies to enable the engineering of ‘designer T cells' with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.
keywords:N/A
$125M
Total Funding
193
Number of Employees
$37.4M
Revenue (est)
21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neogene Therapeutics News
... Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene...
Four Additional Board Members Appointed to Complement Founding Expertise NEW YORK & AMSTERDAM–(BUSINESS WIRE)–October 6, 2020– Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today ...
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The financing was co-led by EcoR1 Capital, Jeito Capital and ...
Neogene Therapeutics Inc. has raised $110 million in venture financing and entered into the race to cure cancers through cell therapies tailored to individual patients. EcoR1 Capital, Jeito Capital and Syncona led the financing, which also included Polaris Partners, Pontifax and seed investors ...
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $53.9M | 193 | 7% | N/A |
#2 | N/A | 194 | 30% | N/A |
#3 | N/A | 194 | 29% | N/A |
#4 | $38.6M | 195 | 6% | N/A |
#5 | $49.2M | 196 | N/A | N/A |